A Phase II Study of CC-90011 in Combination with Nivolumab Immunotherapy in Patients with Advanced Lung Cancer


Full Title

CC-90011-ST-002: A Phase 2, Multicenter, Open-Label, Multicohort Study to Assess Safety and Efficacy of CC-90011 in Combination with Nivolumab in Subjects with Advanced Cancers


In this study, researchers are evaluating the safety and effectiveness of the investigational drug CC-90011 when it is given in combination with nivolumab in patients with advanced small cell lung cancer (SCLC) or squamous non-small cell lung cancer (NSCLC) that has come back or continued to grow despite prior treatment.  

CC-90011 targets an enzyme involved in the growth of some cancers called LSD1. Nivolumab boosts the power of the immune system to detect and destroy cancer cells. CC-90011 is taken orally (by mouth) and nivolumab is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have extensive stage SCLC or stage IIIB-IV squamous NSCLC that came back or continued to grow despite one or two prior regimens of therapy.
  • Patients should recover from the serious side effects of prior treatment before receiving the study treatment.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Victoria Lai at 646-609-3793. Drs. Charles Rudin and Paul Paik are also co-leading this study.





Disease Status

Relapsed or Refractory